Premium
Specific loss of chondromodulin‐I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo
Author(s) -
Hayami Tadashi,
Shukunami Chisa,
Mitsui Kaori,
Endo Naoto,
Tokunaga Kunihiko,
Kondo Jun,
Takahashi Hideaki E.,
Hiraki Yuji
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)01201-6
Subject(s) - chondrosarcoma , in vivo , angiogenesis , cartilage , angiogenesis inhibitor , cancer research , recombinant dna , pathology , adenocarcinoma , medicine , biology , cancer , gene , anatomy , biochemistry , microbiology and biotechnology
Chondromodulin‐I (ChM‐I) was previously identified as an angiogenesis inhibitor in cartilage. Here, we demonstrated that the level of ChM‐I transcripts was substantially reduced to 100 or even less in the lower‐grade chondrosarcomas, in articular cartilage or other benign cartilage tumors. We implanted human chondrosarcoma OUMS‐27 cells into nude mice that reproducibly produced tumors with cartilaginous matrix. Tumor‐induced angiogenesis was evident when the tumors were excised 30 days after implantation. However, the local administration of recombinant human ChM‐I almost completely blocked vascular invasion and tumor growth in vivo. Moreover, ChM‐I also inhibited the growth of HT‐29 colon adenocarcinoma in vivo, implying its therapeutic potential for solid tumors.